Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors
A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining Anaplastic Lymphoma Kinase Inhibitors (ALK Inhibitors) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises ALK Inhibitors administered according to a continuous regimen based on an average daily dose in the range of 10 to 250 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.
1. A method of treating a patient suffering from a non-small cell lung cancer (NSCLC), or metastatic forms thereof, responsive to an Anaplastic Lymphoma Kinase (ALK) Inhibitor and expressing the ELM4-ALK fusion gene and a mutated form of an Epidermal Growth Factor Receptor (EGFR), comprising:
administering to the patient the ALK Inhibitor and an immunogenic polypeptide comprising amino acids cysteine 6 to cysteine 42 of an Epidermal Growth Factor (EGF) at an amount effective to generate an immune response against the EGF, wherein the cysteine residues are numbered relative to amino acids 1 to 52 of SEQ ID NO: 2, or an immunogenic polypeptide comprising SEQ ID NO: 2;
wherein the ALK Inhibitor is selected from the group consisting of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib, and pharmaceutically acceptable salts thereof;
wherein the ALK Inhibitor is administered in a therapeutically effective daily dose in a range of about 10 mg to about 250 mg and the immunogenic polypeptide is administered according to a therapeutically effective repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly to generate polyclonal antibodies targeting EGF.
2. The method of claim 1 , wherein the immunogenic polypeptide is administered prior to the ALK Inhibitor.
3. The method of claim 1 , wherein the immunogenic polypeptide is administered at the same time as the ALK Inhibitor.